WallStreetZenWallStreetZen

NYSEMKT: SER
Serina Therapeutics Inc Stock Forecast, Predictions & Price Target

OverviewForecast
EarningsRevenueDividendOwnership

Analyst price target for SER

Based on 1 analyst offering 12 month price targets for Serina Therapeutics Inc

Min Forecast
$15.00+361.54%
Avg Forecast
$15.00+361.54%
Max Forecast
$15.00+361.54%

Should I buy or sell SER stock?

Based on 1 analyst offering ratings for Serina Therapeutics Inc.

Buy
Strong Buy
0 analysts 0%
Buy
1 analysts 100%
Hold
0 analysts 0%
Sell
0 analysts 0%
Strong Sell
0 analysts 0%

Be the first to know when Wall Street analysts revise their SER stock forecasts and price targets.

SER stock forecasts by analyst

Analyst / FirmRatingActionPrice TargetUpside/DownsideDateAnalyst Color
lockedlocked$00.00+00.00%2025-08-28

1 of 1

Forecast return on equity

Is SER forecast to generate an efficient return?

Company
-734.37%
Industry
259.27%
Market
228.52%
SER's Return on Equity is... subscribe to Premium to read more.
Forecast High Return on Equity Forecast

Forecast return on assets

Is SER forecast to generate an efficient return on assets?

Company
-104.12%
Industry
90.14%
SER is forecast to generate... subscribe to Premium to read more.
Forecast Return on Assets vs Industry Forecast

SER earnings per share forecast

What is SER's earnings per share in the next 3 years based on estimates from 3 analysts?

Avg 1 year Forecast
-$2.15
Avg 2 year Forecast
-$1.79
Avg 3 year Forecast
-$1.34

SER revenue forecast

What is SER's revenue in the next 3 years based on estimates from 3 analysts?

Avg 1 year Forecast
$131.3k+13.19%
Avg 2 year Forecast
$0.0-100%
Avg 3 year Forecast
$0.0-100%
SER's revenue is forecast to... subscribe to Premium to read more.
Forecast High Revenue Growth Forecast

SER revenue growth forecast

How is SER forecast to perform vs Biotechnology companies and vs the US market?

Company
-100%
Industry
102.02%
Market
25.67%
SER's revenues are forecast to... subscribe to Premium to read more.
Forecast Revenue Growth vs Industry Forecast
SER's revenues are forecast to... subscribe to Premium to read more.
Forecast Revenue Growth vs Market Forecast

SER vs Biotech Stocks

TickerPricePrice TargetUp/downsideConsensus
SER$3.25$15.00+361.54%Buy
RNXT$0.94$12.50+1,228.37%Buy
DYAI$0.95$3.00+215.79%Buy
FGEN$8.42$43.00+410.69%Buy
MURA$2.04N/AN/A
View Top Biotech Stocks

Serina Therapeutics Stock Forecast FAQ

Is Serina Therapeutics Stock a good buy in 2025, according to Wall Street analysts?

The consensus among 1 Wall Street analyst covering (NYSEMKT: SER) stock is to Buy SER stock.

Out of 1 analyst, 0 (0%) are recommending SER as a Strong Buy, 1 (100%) are recommending SER as a Buy, 0 (0%) are recommending SER as a Hold, 0 (0%) are recommending SER as a Sell, and 0 (0%) are recommending SER as a Strong Sell.

If you're new to stock investing, here's how to buy Serina Therapeutics stock.

What is SER's earnings growth forecast for 2025-2027?

(NYSEMKT: SER) Serina Therapeutics's forecast annual earnings growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast earnings growth rate of 44.75%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 42.88%.

Serina Therapeutics's earnings in 2025 is -$18,586,000.On average, 3 Wall Street analysts forecast SER's earnings for 2025 to be -$22,941,601, with the lowest SER earnings forecast at -$23,514,261, and the highest SER earnings forecast at -$22,506,507. On average, 3 Wall Street analysts forecast SER's earnings for 2026 to be -$19,064,147, with the lowest SER earnings forecast at -$18,706,901, and the highest SER earnings forecast at -$19,595,218.

In 2027, SER is forecast to generate -$14,325,037 in earnings, with the lowest earnings forecast at -$13,899,541 and the highest earnings forecast at -$14,892,365.

What is SER's revenue growth forecast for 2025-2027?

(NYSEMKT: SER) Serina Therapeutics's forecast annual revenue growth rate of -100% is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 102.02%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 25.67%.

Serina Therapeutics's revenue in 2025 is $116,000.On average, 3 Wall Street analysts forecast SER's revenue for 2025 to be $1,400,192, with the lowest SER revenue forecast at $1,358,602, and the highest SER revenue forecast at $1,455,645. On average, 3 Wall Street analysts forecast SER's revenue for 2026 to be $0, with the lowest SER revenue forecast at $0, and the highest SER revenue forecast at $0.

In 2027, SER is forecast to generate $0 in revenue, with the lowest revenue forecast at $0 and the highest revenue forecast at $0.

What is SER's forecast return on assets (ROA) for 2025-2028?

(NYSEMKT: SER) forecast ROA is -104.12%, which is lower than the forecast US Biotechnology industry average of 90.14%.

What is SER's Price Target?

According to 1 Wall Street analyst that have issued a 1 year SER price target, the average SER price target is $15.00, with the highest SER stock price forecast at $15.00 and the lowest SER stock price forecast at $15.00.

The Wall Street analyst predicted that Serina Therapeutics's share price could reach $15.00 by Aug 28, 2026. The average Serina Therapeutics stock price prediction forecasts a potential upside of 361.54% from the current SER share price of $3.25.

What is SER's Earnings Per Share (EPS) forecast for 2025-2027?

(NYSEMKT: SER) Serina Therapeutics's current Earnings Per Share (EPS) is -$1.87. On average, analysts forecast that SER's EPS will be -$2.15 for 2025, with the lowest EPS forecast at -$2.21, and the highest EPS forecast at -$2.11. On average, analysts forecast that SER's EPS will be -$1.79 for 2026, with the lowest EPS forecast at -$1.75, and the highest EPS forecast at -$1.84. In 2027, SER's EPS is forecast to hit -$1.34 (min: -$1.30, max: -$1.40).

What is SER's forecast return on equity (ROE) for 2025-2028?

(NYSEMKT: SER) forecast ROE is -734.37%, which is considered weak.
©2025 WallStreetZen
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletter
Stock Tools
Top Performing AnalystsStock ScreenerStock ForecastTrending StocksStrong Buy StocksHighest Earnings StocksBest Dividend Paying StocksStatisticsStock Market SectorsStock Market IndustriesHow to Buy Stocks Online
Stock Ideas
Buy The DipBiggest Stock Gainers TodayBiggest Stock Losers Today52 Week High Stocks52 Week Low StocksMost Active Stocks TodayMost Undervalued StocksBest Penny Stocks to Buy NowBest Stocks Under $5Best Stocks Under $10
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.